A Phase 4 interventional study of Everolimus and Cyclosporine in Heart Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 3 countries. Per ClinicalTrials.gov, last updated 2019-10-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Graft vs Host Disease by Novartis — 2 open to participants now, 4 under way, none of them phase 3. Graft vs Host Disease · Novartis.
Among the 12 studies in Graft vs Host Disease by Novartis, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 4, and was the 5th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →2 of the 12 studies in Graft vs Host Disease by Novartis are open now, in 2 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan
Ages 0+
Novartis Pharmaceuticals · Sites in China
Ages 12–100
By country, each count listing its studies:
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3 · Phase 4 5
First in 2012; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 84 across the 10 interventional studies, 268 across the 2 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Graft vs Host Disease by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7 years) of early initiation of everolimus and early elimination of CsA compared to standard immunosuppressive regimen including CsA on primary and secondary endpoints investigated in the SCHEDULE (NCT01266148) main study.
This protocol was written to describe the procedures for a single 5, 6 or 7 year follow-up control visit of patients who participated in the 12-month SCHEDULE (NCT01266148) study and the following 3-year follow-up examination/visit. The aim of this 5 to 7-year follow-up visit was to examine the effect of long term treatment, i.e. 5, 6 or 7 years, with early initiation of everolimus (Certican®) and early elimination of cyclosporine (CsA), compared to standard immunosuppressive regimen including CsA, on renal and heart function. During the time period of this follow-up examinations, this visit was performed as part of a routine annual visit 5, 6 or 7 years since transplantation (and inclusion in the original SCHEDULE study).
Study code of SCHEDULE, the core study: CRAD001ANO02 (EudraCT No.: 2009-013074-41)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
Drug: Everolimus
patients received standard CsA, MMF and corticosteroids
Drug: Cyclosporine · Drug: Mycophenolate mofetil · Drug: Corticosteroids
All patients, independent of their initial randomization in the core study, were followed up as in one single group Commercially available everolimus (Certican®), oral route, was used.
Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Measured Glomerular Filtration Rate (mGFR)
Renal function as assessed by measured Glomerular Filtration Rate (mGFR) (Cr-EDTA or iohexol clearance). Baseline Visit 1 and Patient 4252 excluded from the intent treat analysis set.
Time frame: at the 5-7 year follow-up visit
Progression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS)
Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.
Time frame: within 5-7 years
Percent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.
Time frame: at the 5-7 year follow-up
Myocardial Structure and Function
Myocardial structure and function by echocardiography assessment measured by ventricular end systolic diameter.
Time frame: within 5-7 years
Quality of Life by SF-36 Change From Pre-transplantation to 5-7 Year Follow-up
This Quality of life Short Form Survey with 36 items (Minnesota Living with Heart Failure Questionnaire)was administered to patients pre-transplantation and after transplantation at the 5-7 year visit. This data represents the change. The survey consist of scores on a scale. Each form is scaled from 0 t 100. 0 = maximum disability and 100 equals no disability.
Time frame: at the 5-7 year visit
Change From Baseline in the Euro Quality of Life 5D
Change from baseline in Euro Quality of Life-5D from 3 Year Follow-Up to 5 to 7 Year Follow-Up Baseline Visit 1 (ITT Set) Euro Quality of Life 5D (EQ-5D): is a descriptive system of healthrelated quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) each of which can be assessed as one of three levels of severity (no problems/some or moderate problems/extreme problems). A Visual Analogue Scale (VAS)-scale is also included in the EQ-5D questionnaire. The EQ-5D index is calculated based on the United Kingdom Time Trade-Off (TTO) N3 value set which converts the five dimensions scores into a single measure with a possible range from -0.163 (worst possible health state) to +1 (perfect health). A positive change from baseline indicates an improvement in Quality of Life.
Time frame: Baseline, 5-7 year visit
Change From Baseline in Visual Analog Scale (VAS)
Change in visual analog scale (VAS) from baseline to the 5 to 7 Year follow up visit. 0 is no pain; and 10 is the worst possible pain
Time frame: baseline, at the 5-7 year visit
Number of Participants With Beck Depression Inventory (BDI)
Beck Depression Inventory (BDI) Score has the following categories of depression. Normal, Mild, Moderate Severe and Missing.
Time frame: at the 5-7 year visit
In total, 95 patients (48 everolimus, 47 controls), attended the follow-up visit at 5-7 years post-transplant and were included in the safety population The PP population (27 everolimus, 35 controls) excluded 7 patients in the everolimus group and 11 in the control group who discontinued study drug prematurely
| Milestone | Everolimus | Control |
|---|---|---|
| Started | 48 | 47 |
| Safety set | 48 | 47 |
| Intent to treat | 46 | 47 |
| Completed | 48 | 47 |
| Not completed | 0 | 0 |
Renal function as assessed by measured Glomerular Filtration Rate (mGFR) (Cr-EDTA or iohexol clearance). Baseline Visit 1 and Patient 4252 excluded from the intent treat analysis set.
| mL/min/1.73m2 | Everolimus | Control |
|---|---|---|
| Measured Glomerular Filtration Rate (mGFR) | 74.7 ± 23.3 | 62.4 ± 16.5 |
Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.
| mm | Everolimus | Control |
|---|---|---|
| Progression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS) | 0.13 ± 0.15 | 0.23 ± 0.24 |
Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT) ≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence.
| percent of participants | Everolimus | Control |
|---|---|---|
| Percent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV) | 53 | 74 |
Myocardial structure and function by echocardiography assessment measured by ventricular end systolic diameter.
| cm | Everolimus | Control |
|---|---|---|
| LVESD (left ventricular end systolic diameter) | 3.1 ± 0.8 | 3.1 ± 0.6 |
| LVEDD (left ventricular end diastolic diameter) | 4.7 ± 0.6 | 4.9 ± 0.6 |
This Quality of life Short Form Survey with 36 items (Minnesota Living with Heart Failure Questionnaire)was administered to patients pre-transplantation and after transplantation at the 5-7 year visit. This data represents the change. The survey consist of scores on a scale. Each form is scaled from 0 t 100. 0 = maximum disability and 100 equals no disability.
| scores on a scale | Everolimus | Control |
|---|---|---|
| Physical Health Summary | 16.8 ± 15.0 | 13.2 ± 13.3 |
| Mental Health Summary | 10.4 ± 10.5 | 15.3 ± 15.5 |
| Physical Functioning | 36.7 ± 38.4 | 40.8 ± 30.4 |
| Role Physical | 50.2 ± 32.3 | 55.1 ± 32.4 |
| Bodily Pain | 10.3 ± 34.8 | 7.2 ± 34.1 |
| General Health | 25.7 ± 26.4 | 23.4 ± 25.6 |
| Vitality | 30.0 ± 25.8 | 28.9 ± 29.0 |
| Social Functioning | 39.9 ± 31.5 | 43.9 ± 32.4 |
| Role Emotional | 23.8 ± 36.7 | 42.8 ± 46.5 |
| Mental Health | 8.6 ± 17.2 | 14.4 ± 25.8 |
Change from baseline in Euro Quality of Life-5D from 3 Year Follow-Up to 5 to 7 Year Follow-Up Baseline Visit 1 (ITT Set) Euro Quality of Life 5D (EQ-5D): is a descriptive system of healthrelated quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) each of which can be assessed as one of three levels of severity (no problems/some or moderate problems/extreme problems). A Visual Analogue Scale (VAS)-scale is also included in the EQ-5D questionnaire. The EQ-5D index is calculated based on the United Kingdom Time Trade-Off (TTO) N3 value set which converts the five dimensions scores into a single measure with a possible range from -0.163 (worst possible health state) to +1 (perfect health). A positive change from baseline indicates an improvement in Quality of Life.
| scores on the scale | Everolimus | Control |
|---|---|---|
| Change From Baseline in the Euro Quality of Life 5D | 0.2323 ± 0.3849 | 0.2982 ± 0.3274 |
Change in visual analog scale (VAS) from baseline to the 5 to 7 Year follow up visit. 0 is no pain; and 10 is the worst possible pain
| mm | Everolimus | Control |
|---|---|---|
| Change From Baseline in Visual Analog Scale (VAS) | 35.6 ± 26.9 | 34.0 ± 32.0 |
Beck Depression Inventory (BDI) Score has the following categories of depression. Normal, Mild, Moderate Severe and Missing.
| Participants | Everolimus | Control |
|---|---|---|
| Normal | 15 | 13 |
| Mild | 6 | 4 |
| Moderate | 2 | 5 |
| Severe | 1 | 0 |
| Missing | 3 | 5 |
Collected over An average of 3 years (from the 3 year follow-up visit to the 5-7 year follow-up visit). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus | 0/48 (0%) | 26/48 (54.2%) | 15/48 (31.3%) |
| Control | 0/47 (0%) | 18/47 (38.3%) | 4/47 (8.5%) |
| Event | Everolimus | Control |
|---|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 13/48 | 3/47 |
| PneumoniaInfections and infestations | 13/48 | 3/47 |
| DiarrhoeaGastrointestinal disorders | 0/48 | 2/47 |
| Upper respiratory tract infectionInfections and infestations | 2/48 | 2/47 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/48 | 2/47 |
| Cardiac failureCardiac disorders | 2/48 | 0/47 |
| DiverticulitisInfections and infestations | 2/48 | 0/47 |
| SepsisInfections and infestations | 2/48 | 0/47 |
| SyncopeNervous system disorders | 2/48 | 0/47 |
| DepressionPsychiatric disorders | 2/48 | 0/47 |
| Event | Everolimus | Control |
|---|---|---|
| PneumoniaInfections and infestations | 8/48 | 2/47 |
| Oedema peripheralGeneral disorders | 5/48 | 0/47 |
| DiarrhoeaGastrointestinal disorders | 4/48 | 3/47 |
| SepsisInfections and infestations | 3/48 | 0/47 |
The Intention-to-Treat Set (ITT Set) consists of patients who: * were included in the ITT in the Clinical Study Reports Addendum dated 11 August 2015 for the 3 year Follow-up visit * had at least one assessment of the efficacy variables mGFR or cGFR at the 5 to 7 year Follow-up
| Age, Continuous(Years) | Everolimus | Control | Total |
|---|---|---|---|
| Mean | 50.13 ± 13.43 | 52.11 ± 11.61 | 51.11 ± 12.53 |
| Sex: Female, Male(Participants) | Everolimus | Control | Total |
|---|---|---|---|
| Female | 13 | 12 | 25 |
| Male | 35 | 35 | 70 |
| Race (NIH/OMB)(Participants) | Everolimus | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 47 | 44 | 91 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2016 to primary completion in Sep 2017, 20 months.
Results were first posted in Oct 2019, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus